These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 25758812

  • 1. Decreased tumor apparent diffusion coefficient correlates with objective response of pediatric low-grade glioma to bevacizumab.
    Hsu CH, Lober RM, Li MD, Partap S, Murphy PA, Barnes PD, Fisher PG, Yeom KW.
    J Neurooncol; 2015 May; 122(3):491-6. PubMed ID: 25758812
    [Abstract] [Full Text] [Related]

  • 2. Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma.
    McDonald CR, Delfanti RL, Krishnan AP, Leyden KM, Hattangadi-Gluth JA, Seibert TM, Karunamuni R, Elbe P, Kuperman JM, Bartsch H, Piccioni DE, White NS, Dale AM, Farid N.
    Neuro Oncol; 2016 Nov; 18(11):1579-1590. PubMed ID: 27106406
    [Abstract] [Full Text] [Related]

  • 3. Single-agent bevacizumab in the treatment of recurrent or refractory pediatric low-grade glioma: A single institutional experience.
    Gorsi HS, Khanna PC, Tumblin M, Yeh-Nayre L, Milburn M, Elster JD, Crawford JR.
    Pediatr Blood Cancer; 2018 Sep; 65(9):e27234. PubMed ID: 29750399
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients.
    Zhang M, Gulotta B, Thomas A, Kaley T, Karimi S, Gavrilovic I, Woo KM, Zhang Z, Arevalo-Perez J, Holodny AI, Rosenblum M, Young RJ.
    Neuro Oncol; 2016 May; 18(5):735-43. PubMed ID: 26538618
    [Abstract] [Full Text] [Related]

  • 6. [Evaluation of ADC mapping as an early predictor for tumor response to chemotherapy in recurrent glioma treated with bevacizumab/irinotecan: proof of principle].
    Ringelstein A, Turowski B, Gizewski ER, Schroeteler J, Rapp M, Saleh A, Lanzman RS, Mathys C, Sabel M, Mödder U.
    Rofo; 2010 Oct; 182(10):868-72. PubMed ID: 20740393
    [Abstract] [Full Text] [Related]

  • 7. Advantages of high b-value diffusion-weighted imaging to diagnose pseudo-responses in patients with recurrent glioma after bevacizumab treatment.
    Yamasaki F, Kurisu K, Aoki T, Yamanaka M, Kajiwara Y, Watanabe Y, Takayasu T, Akiyama Y, Sugiyama K.
    Eur J Radiol; 2012 Oct; 81(10):2805-10. PubMed ID: 22100373
    [Abstract] [Full Text] [Related]

  • 8. Focal changes in diffusivity on apparent diffusion coefficient MR imaging and amino acid uptake on PET do not colocalize in nonenhancing low-grade gliomas.
    Rahm V, Boxheimer L, Bruehlmeier M, Berberat J, Nitzsche EU, Remonda L, Roelcke U.
    J Nucl Med; 2014 Apr; 55(4):546-50. PubMed ID: 24566001
    [Abstract] [Full Text] [Related]

  • 9. Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients.
    Rieger J, Bähr O, Müller K, Franz K, Steinbach J, Hattingen E.
    J Neurooncol; 2010 Aug; 99(1):49-56. PubMed ID: 20035366
    [Abstract] [Full Text] [Related]

  • 10. Apparent diffusion coefficient changes predict survival after intra-arterial bevacizumab treatment in recurrent glioblastoma.
    Galla N, Chiang G, Chakraborty S, Singh R, John Tsiouris A, Boockvar J, Kovanlikaya I.
    Neuroradiology; 2017 May; 59(5):499-505. PubMed ID: 28343250
    [Abstract] [Full Text] [Related]

  • 11. Bevacizumab for symptomatic radiation-induced tumor enlargement in pediatric low grade gliomas.
    Foster KA, Ares WJ, Pollack IF, Jakacki RI.
    Pediatr Blood Cancer; 2015 Feb; 62(2):240-245. PubMed ID: 25382690
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Longitudinal restriction spectrum imaging is resistant to pseudoresponse in patients with high-grade gliomas treated with bevacizumab.
    Kothari P, White NS, Farid N, Chung R, Kuperman JM, Girard HM, Shankaranarayanan A, Kesari S, McDonald CR, Dale AM.
    AJNR Am J Neuroradiol; 2013 Sep; 34(9):1752-1757. PubMed ID: 23578667
    [Abstract] [Full Text] [Related]

  • 14. Confirmation of Bevacizumab Activity, and Maintenance of Efficacy in Retreatment After Subsequent Relapse, in Pediatric Low-grade Glioma.
    Kalra M, Heath JA, Kellie SJ, Dalla Pozza L, Stevens MM, Swamy S, McCowage GB.
    J Pediatr Hematol Oncol; 2015 Aug; 37(6):e341-6. PubMed ID: 26056795
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Diffusion restriction associated with bevacizumab treatment in recurrent glial tumors, evaluation of survival with ADC measurement analysis.
    Savran B, Göç MF, Öztürk FU, Duran AO, Ünal Ö.
    Eur Rev Med Pharmacol Sci; 2023 May; 27(9):4153-4161. PubMed ID: 37203841
    [Abstract] [Full Text] [Related]

  • 20. ADC texture--an imaging biomarker for high-grade glioma?
    Brynolfsson P, Nilsson D, Henriksson R, Hauksson J, Karlsson M, Garpebring A, Birgander R, Trygg J, Nyholm T, Asklund T.
    Med Phys; 2014 Oct; 41(10):101903. PubMed ID: 25281955
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.